Manifesto on inhaled triple therapy in asthma: an Interasma (Global Asthma Association - GAA) document

J Asthma. 2022 Dec;59(12):2402-2412. doi: 10.1080/02770903.2021.2022160. Epub 2022 Jan 11.

Abstract

Objective: The optimal use of drug combinations for the management of asthma is providing significant results. This has prompted Interasma (Global Asthma Association) to take a position on inhaled triple therapy in asthma.Methods: We performed an extensive literature research to clinical trials, meta-analyses, randomized controlled trials and systematic reviews.Results: Starting from an extensive literature review, Interasma executive committee discussed and approved this Manifesto, developed by Interasma scientific network (INES) members.Conclusions: The manifesto describes the evidence gathered to date and states, advocates, and proposes issues on inhaled corticosteroid (ICS) plus long-acting beta 2 agonist (LABA) and long-acting muscarinic antagonists (LAMA) with the aim of challenging assumptions, fostering commitment, and bringing about change.

Keywords: Asthma management; Interasma; asthma control; asthma pharmacotherapy; asthma treatment; consensus; manifesto.

MeSH terms

  • Administration, Inhalation
  • Adrenal Cortex Hormones / therapeutic use
  • Adrenergic beta-2 Receptor Agonists / therapeutic use
  • Asthma* / drug therapy
  • Bronchodilator Agents / therapeutic use
  • Drug Therapy, Combination
  • Humans
  • Pulmonary Disease, Chronic Obstructive* / drug therapy

Substances

  • Adrenergic beta-2 Receptor Agonists
  • Bronchodilator Agents
  • Adrenal Cortex Hormones